Some recent studies have demonstrated that finasteride, a wellknown 5 -reductase inhibitor, can decrease prostate specific antigen (PSA) by approximately 50% during the first 1 year of treatment. We investigated how long-term treatment with finasteride and -blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia (BPH).
Purpose:
Some recent studies have demonstrated that finasteride, a wellknown 5 -reductase inhibitor, can decrease prostate specific antigen (PSA) by approximately 50% during the first 1 year of treatment. We investigated how long-term treatment with finasteride and -blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia (BPH).
Materials and Methods:
In a retrospective trial, we evaluated a total of 293 men with lower urinary tract symptoms (LUTS) that were suggestive of BPH. These men were divided into two treatment groups: group A was treated with -blockers and group C was treated with a combination of finasteride and -blocker. Comparisons of the two groups were performed by using independent t-tests. The changes in the PSA concentrations from baseline to the time of the final measurements were determined by repeated measures of ANOVA. Results: There was no significant difference in the baseline PSA between the two groups. A statistically significant reduction in the PSA levels was observed at 2 years in C group (p 0.05), whereas any significant increase were not observed in group A (p 0.05). In group A, the repeatedly measured PSA levels were 2.67, 2.40, 2.41 and 2.42, respectively. In C group, these were 3.22, 2.09, 1.81 and 1.71 respectively. Conclusions: Our data showed that there was no clinically significant effect of long term treatment with -blocker on the PSA levels. However, finasteride had significant effect on the serum PSA level during first two years of treatment. 
